Avineuro Pharmaceuticals, Inc announced the initiation of phase-I clinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. The results of phase-I studies are expected to be available in May 2009. Based on these and other results, Avineuro Pharma plans to advance AVN-101 into phase-II clinical trials in Q2 2009. Avineuro Pharma presented at the ninth International Conference - AD/PD 2009 - Prague, Czech Republic, March 11-15, 2009.

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.